Background: Immunological treatments (immune checkpoint inhibitors, chimeric antigen receptor T cells, Bi-specific T-cell engagers) have deeply changed the treatment of several cancers. However, the impact of these treatments on the risk of developing infections has not been completely ascertained, yet. Methods: We reviewed all the registration studies of currently approved immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T cells) and Bi-specific T-cell engagers (BiTEs) to collect all the reported infections. For each drug, we have generated a report with the infections occurring in at least 10% of the patients enrolled. Results: The most frequently reported infections involving ICIs-treated patients involved the respiratory tract, including nasopharyngitis, upper respiratory tract infections and pneumonia, and the urinary tract. Among those treated with CAR-T cells, were frequently reported the incidence of unspecified infections and infestations, bacterial and viral infections. In patients treated with BiTEs, nasopharyngitis, pneumonia and device-related infections were the most frequently reported conditions. Conclusions: A wide range of infections are reported in registration studies and clinical trials of ICIs, CAR-T cells and BiTEs.

Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells and Bi-specific T-cell engagers: a review of registration studies / A. Lombardi, A. Saydere, R. Ungaro, G. Bozzi, G. Viero, A. Bandera, A. Gori, M.U. Mondelli. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 120:(2022), pp. 77-82. [10.1016/j.ijid.2022.04.022]

Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells and Bi-specific T-cell engagers: a review of registration studies

A. Lombardi
;
R. Ungaro;G. Bozzi;G. Viero;A. Bandera;A. Gori;
2022

Abstract

Background: Immunological treatments (immune checkpoint inhibitors, chimeric antigen receptor T cells, Bi-specific T-cell engagers) have deeply changed the treatment of several cancers. However, the impact of these treatments on the risk of developing infections has not been completely ascertained, yet. Methods: We reviewed all the registration studies of currently approved immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T cells) and Bi-specific T-cell engagers (BiTEs) to collect all the reported infections. For each drug, we have generated a report with the infections occurring in at least 10% of the patients enrolled. Results: The most frequently reported infections involving ICIs-treated patients involved the respiratory tract, including nasopharyngitis, upper respiratory tract infections and pneumonia, and the urinary tract. Among those treated with CAR-T cells, were frequently reported the incidence of unspecified infections and infestations, bacterial and viral infections. In patients treated with BiTEs, nasopharyngitis, pneumonia and device-related infections were the most frequently reported conditions. Conclusions: A wide range of infections are reported in registration studies and clinical trials of ICIs, CAR-T cells and BiTEs.
Bi-specific T-cell engagers; cancer treatment; chimeric antigen receptor T cells; immune checkpoint inhibitors; infections
Settore MED/17 - Malattie Infettive
2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1201971222002211-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 405.25 kB
Formato Adobe PDF
405.25 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/925331
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact